What is AOD-9604?
AOD-9604 is a synthetic peptide copying the tail end (residues 177 to 191) of human growth hormone, intended to keep the fat burning activity of growth hormone without its effects on growth and blood sugar. In obese mice it increased fat burning and reduced weight gain without raising IGF-1 (a growth factor made in response to growth hormone) or glucose, but no human trial indexed in PubMed demonstrates weight loss and the sponsor's obesity program ended in the mid 2000s. FDA placed it in 503A Category 2 (compounding ingredients FDA flagged for significant safety risks) in 2023; the nomination was later withdrawn, so it is no longer in Category 2 but has no federal basis to be compounded (custom-made by a pharmacy), and it is prohibited by WADA (the World Anti-Doping Agency).
AOD-9604 is a synthetic 16 amino acid C terminal fragment of human growth hormone (residues 177 to 191 with an N terminal tyrosine). It is also known as AOD9604, Anti-obesity drug 9604, hGH fragment 177-191 (tyrosine modified), Tyr-hGH 177-191, AOD-9604 acetate, AOD 9604, AOD-9604 peptide.
How does it work?
The 177 to 191 region of growth hormone is proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue, possibly through beta-3 adrenergic receptor dependent pathways, without binding the GH receptor in the way full length GH does. In mice it did not raise IGF-1, glucose, or insulin. Whether this mechanism operates in humans at the doses used has not been shown.
| Cluster | Metabolic and growth hormone axis |
|---|---|
| Routes | Subcutaneous injection (as sold); Oral and injectable (mouse studies); Topical and intra-articular (promoted online, no published data) |
| Conditions studied | Obesity and chronic weight management; Fat loss and body composition |
| Record | v3, reviewed, verified Sep 29, 2026 |
AOD-9604 benefits: what the evidence shows
Rodent studies from one Australian group around 2000 to 2001 showed AOD-9604 increased fat oxidation, reduced body weight gain, and lowered fat mass in obese mice, with the effect absent in beta-3 adrenergic receptor knockout mice. The sponsor ran randomized human obesity trials in the early 2000s, but no indexed publication reports a meaningful weight loss benefit and the program was discontinued. PeptideAgent therefore grades the evidence animal-only; the human trials that exist did not produce a positive published result.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 0 | n/a |
| Animal studies | 3 | n/a |
| All indexed studies | 3 | n/a |
Human evidence
No indexed human randomized trial reporting weight loss identified. The sponsor's phase 2 obesity trials in the early 2000s were not published in an indexed journal and the program was discontinued, which is consistent with a lack of efficacy. FDA's Category 2 rationale states it identified only limited safety information and serious adverse events with unclear causality. Newer uses promoted online (joint and cartilage repair) have no published human data.
Animal evidence
Ng 2000: metabolic studies in rodents showed the synthetic lipolytic domain increased lipolysis and inhibited lipogenesis without the diabetogenic effects of GH. Heffernan 2001 (Endocrinology): chronic treatment in obese mice reduced weight gain and fat mass, with the effect lost in beta-3 adrenergic receptor knockout mice. Heffernan 2001 (Int J Obes): chronic treatment of obese mice with hGH or the modified C terminal fragment increased fat oxidation and produced weight loss. Doses in mice were on the order of 250 ug/kg to 2 mg/kg per day.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone2000 PMID 11146367 | Rodent metabolic pharmacologyRats and mice | The synthetic 177 to 191 fragment stimulated lipolysis and inhibited lipogenesis without GH like effects on glucose or IGF-1 | Evidence: Animal-only evidence |
| The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice2001 PMID 11713213 | Chronic treatment study in obese and knockout miceObese mice and beta-3 adrenergic receptor knockout mice | Reduced weight gain and fat mass in obese mice; effect absent in beta-3 receptor knockouts | Evidence: Animal-only evidence |
| Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment2001 PMID 11673763 | Chronic treatment study in obese miceObese mice | Increased fat oxidation and weight loss with the modified C terminal fragment | Evidence: Animal-only evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Obesity and chronic weight management | Evidence: Animal-only evidence | Small older human trials reported no meaningful weight loss and are not indexed as controlled trials in the evidence table, so they do not raise the grade; not approved. |
| Fat loss and body composition | Evidence: Animal-only evidence | Increased fat oxidation in obese mice; small human studies reported no meaningful fat loss and do not raise the grade. |
Is AOD-9604 legal in the United States?
FDA and compounding status
Not FDA approved. FDA previously placed AOD-9604 in 503A Category 2, citing immunogenicity risk, limited safety information, and serious adverse events with unclear causality. FDA's Category 2 page now lists AOD-9604 under bulk drug substances nominated but withdrawn, so it is no longer in any 503A category and is outside FDA's interim enforcement policy. At its December 4, 2024 meeting the Pharmacy Compounding Advisory Committee voted 0 to 12 against placing AOD-9604 on the 503A bulks list. It is not on that list, has no FDA approved product, and was not part of the July 2026 review, so as of the last verification date a compounding pharmacy has no federal basis to use it.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
Full tracker for AOD-9604 or the category-wide tracker.
Email me when AOD-9604's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of AOD-9604 used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. Mouse studies used roughly 250 ug/kg to 2 mg/kg per day orally or by injection; these rodent ranges do not translate to a human dose, and the unpublished human trials do not provide a citable regimen.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous injection (as sold) |
| 2 | Oral and injectable (mouse studies) |
| 3 | Topical and intra-articular (promoted online, no published data) |
AOD-9604 side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | No systematic human safety data published |
| 2 | FDA cites serious adverse events possibly associated with AOD-9604 with unclear causality |
| 3 | Injection site reactions reported anecdotally |
| 4 | Headache and nausea reported anecdotally |
| 5 | Immunogenicity risk from aggregation and impurities (FDA Category 2 rationale) |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies exist |
| 2 | In mice it did not change glucose or IGF-1, so interactions with diabetes medications are theoretical rather than observed |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Pregnancy and breastfeeding (no data) |
| 2 | Athletes subject to WADA testing (prohibited at all times under S2) |
| 3 | Any use requiring an approved product: none exists |
How do people access AOD-9604 legally?
Typical cost: Not available through licensed US channels since the 2023 Category 2 placement. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
No lawful United States access path identified on the last verified date; the 503A nomination was withdrawn and it is not on the bulks list.
Not available
Not available as an FDA approved product; a 503A pharmacy has no listed basis to compound it.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare AOD-9604
What's actually offered, and what that means for you
FDA has found compounding pharmacies offering AOD-9604 anyway. [8] [9]
Being offered does not change the legal status of AOD-9604. AOD-9604 is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [4] [5]
What FDA found
- January 2022: A compounding pharmacy had made an AOD-9604 injection and recalled it in July 2021 because sterility could not be assured. [9]
- April 2020: FDA named AOD-9604 among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [8]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [4] [10] [11] [12] [13] [14]
What that means for you
- A pharmacy that compounds AOD-9604 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [10] [11]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [14]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [15]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [16] [17]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [4]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, AOD-9604 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [6]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound AOD-9604, with or without a prescription. [5]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [18] [19] [20]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [20] [21] [22]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [14] [23] [24] [25] [26] [27]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [14]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [18]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [22]
- Pharmacy: Is this made for me on a prescription written in my name? [21]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [20] [22]
- Prescriber: What is the legal basis for a pharmacy to compound AOD-9604? Is it FDA approved or on the 503A bulks list? [5] [14]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [22]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [15]
Frequently asked questions
What is AOD-9604?
AOD-9604 is a synthetic copy of the tail end of human growth hormone (residues 177 to 191, with an added tyrosine), designed to keep growth hormone's fat burning effect without its growth promoting effects. In obese mice it increased fat burning (fat oxidation) and reduced weight gain. It is not FDA approved, it is off the FDA Category 2 list (compounding ingredients flagged for significant safety risks) only because its nomination was withdrawn, and it has no lawful compounded source. [1] [3] [4]
Is AOD-9604 legal in the United States?
It is not FDA approved and has no federal basis to be compounded from bulk. FDA placed it in 503A Category 2 in 2023, and although the nomination has since been withdrawn (so it is no longer listed in Category 2 as of April 2026), it has no place on the 503A bulks list, which leaves compounding pharmacies without a federal basis to make it. Possession is not a crime; research chemical products are not for human use. [4] [5]
Does AOD-9604 work for weight loss?
In obese mice, yes: it increased fat oxidation and reduced fat mass without raising blood sugar or IGF-1. In humans, no published trial shows it works. The sponsor ran randomized obesity trials in the early 2000s and discontinued the program without publishing a positive result. PeptideAgent grades the evidence animal-only. [1] [2] [3]
What are the side effects of AOD-9604?
There is no systematic human safety data in the indexed literature. FDA's Category 2 rationale notes it identified serious adverse events that may be associated with AOD-9604, though causality is not clear, and flags immunogenicity risk from peptide impurities. Injection site reactions, headache, and nausea are reported anecdotally. [4]
How is AOD-9604 taken?
Products sold to people are subcutaneous injection vials, and some clinics have promoted oral, topical, and joint injection use. None of these routes has a published human dose, and mouse study doses do not translate to a human regimen. PeptideAgent does not give doses for unapproved peptides. [1] [2]
How much does AOD-9604 cost?
It is no longer available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [4] [7]
Is AOD-9604 banned by WADA?
Yes. The WADA Prohibited List names growth hormone fragments, including AOD-9604 and hGH 176-191, under section S2, prohibited at all times. [6]
AOD-9604 vs semaglutide for fat loss: how do they compare?
They are not comparable in evidence. Semaglutide has large randomized trials showing about 15% average weight loss over 68 weeks and is FDA approved. AOD-9604 has mouse data and no published human trial showing weight loss, and it is not available through licensed channels. Anyone offered AOD-9604 for weight loss is being offered an unproven product in place of proven ones. [2] [4]
Does AOD-9604 help joints or cartilage?
There is no published human evidence for joint repair. The claim comes from marketing and from a small amount of animal work on osteoarthritis models. No randomized trial in people with joint pain or cartilage injury has been published. [4]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000PubMed 11146367, 2000
- [2]Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001PubMed 11713213, 2001
- [3]Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord 2001PubMed 11673763, 2001
- [4]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA, 2026
- [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
- [6]WADA Prohibited List, section S2 (growth hormone fragments, e.g. AOD-9604 and hGH 176-191)WADA, 2026
- [7]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [8]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
- [9]FDA warning letter 624782, January 26, 2022, to a compounding pharmacy (FDA warning letters database)FDA, 2022
- [10]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 29). AOD-9604: evidence, legality, and access. https://peptideagent.ai/peptides/aod-9604- HTML link
<a href="https://peptideagent.ai/peptides/aod-9604">AOD-9604: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.